Yoshitsu Co., Ltd Entered into US$2.75 Million Strategic Loan with Best Life Technology Limited
Yoshitsu Co., (Nasdaq: TKLF), a retailer and wholesaler of Japanese products, announced that its Hong Kong subsidiary, Tokyo Lifestyle (TLS), has secured a US$2.75 million strategic loan from Best Life Technology , a subsidiary of Tasly, a Chinese pharmaceutical conglomerate. The loan agreement, signed on July 10, 2024, has a one-year term from July 15, 2024, to July 14, 2025.
This funding follows a strategic cooperation agreement between Yoshitsu and Tasly in October 2023, focusing on global health product research, development, and sales. Yoshitsu's Principal Executive Officer, Mei Kanayama, expressed confidence that this loan will support the company's growth initiatives and market expansion efforts.
Yoshitsu Co., (Nasdaq: TKLF), un rivenditore e grossista di prodotti giapponesi, ha annunciato che la sua filiale di Hong Kong, Tokyo Lifestyle (TLS), ha ottenuto un prestito strategico di 2,75 milioni di dollari USA da Best Life Technology, una sussidiaria di Tasly, un conglomerato farmaceutico cinese. L'accordo di prestito, firmato il 10 luglio 2024, ha un termine di un anno dal 15 luglio 2024 al 14 luglio 2025.
Questo finanziamento segue un accordo di cooperazione strategica tra Yoshitsu e Tasly nell'ottobre 2023, che si concentra sulla ricerca, sviluppo e vendita di prodotti per la salute globale. Mei Kanayama, amministratore delegato di Yoshitsu, ha espresso fiducia nel fatto che questo prestito supporterà le iniziative di crescita dell'azienda e gli sforzi di espansione del mercato.
Yoshitsu Co., (Nasdaq: TKLF), un minorista y mayorista de productos japoneses, anunció que su filial en Hong Kong, Tokyo Lifestyle (TLS), ha asegurado un préstamo estratégico de 2.75 millones de dólares estadounidenses de Best Life Technology, una subsidiaria de Tasly, un conglomerado farmacéutico chino. El acuerdo de préstamo, firmado el 10 de julio de 2024, tiene un plazo de un año desde el 15 de julio de 2024 hasta el 14 de julio de 2025.
Este financiamiento sigue a un acuerdo de cooperación estratégica entre Yoshitsu y Tasly en octubre de 2023, que se centra en la investigación, desarrollo y venta de productos de salud global. Mei Kanayama, CEO de Yoshitsu, expresó confianza en que este préstamo apoyará las iniciativas de crecimiento de la compañía y sus esfuerzos de expansión en el mercado.
Yoshitsu Co., (Nasdaq: TKLF), 일본 제품의 소매업체이자 도매업체는 홍콩 자회사인 Tokyo Lifestyle (TLS)가 중국 제약 대기업 Tasly의 자회사인 Best Life Technology로부터 275만 달러의 전략적 대출을 확보했다고 발표했습니다. 대출 계약은 2024년 7월 10일에 서명되었으며, 1년의 대출 기간은 2024년 7월 15일부터 2025년 7월 14일까지입니다.
이 자금은 2023년 10월에 Yoshitsu와 Tasly 간의 전략적 협력 계약에 따른 것으로, 글로벌 건강 제품의 연구, 개발 및 판매에 중점을 두고 있습니다. Yoshitsu의 최고 경영자 Mei Kanayama는 이 대출이 회사의 성장 계획과 시장 확장 노력에 도움이 될 것이라고 확신했습니다.
Yoshitsu Co., (Nasdaq: TKLF), un détaillant et grossiste de produits japonais, a annoncé que sa filiale à Hong Kong, Tokyo Lifestyle (TLS), a obtenu un prêt stratégique de 2,75 millions de dollars US de Best Life Technology, une filiale de Tasly, un conglomérat pharmaceutique chinois. L'accord de prêt, signé le 10 juillet 2024, a une durée d'un an du 15 juillet 2024 au 14 juillet 2025.
Ce financement fait suite à un accord de coopération stratégique entre Yoshitsu et Tasly en octobre 2023, axé sur la recherche, le développement et la vente de produits de santé mondiaux. Mei Kanayama, PDG de Yoshitsu, a exprimé sa confiance dans le fait que ce prêt soutiendra les initiatives de croissance de l'entreprise et ses efforts d'expansion sur le marché.
Yoshitsu Co., (Nasdaq: TKLF), ein Einzelhändler und Großhändler für japanische Produkte, gab bekannt, dass seine Tochtergesellschaft in Hongkong, Tokyo Lifestyle (TLS), ein strategisches Darlehen in Höhe von 2,75 Millionen US-Dollar von Best Life Technology, einer Tochtergesellschaft des chinesischen Pharma-Konglomerats Tasly, gesichert hat. Der Darlehensvertrag, der am 10. Juli 2024 unterzeichnet wurde, hat eine Laufzeit von einem Jahr, vom 15. Juli 2024 bis zum 14. Juli 2025.
Diese Finanzierung folgt einem strategischen Kooperationsvertrag zwischen Yoshitsu und Tasly im Oktober 2023, der sich auf Forschung, Entwicklung und Vertrieb von Gesundheitsprodukten auf globaler Ebene konzentriert. Mei Kanayama, die Geschäftsführerin von Yoshitsu, äußerte Vertrauen darin, dass dieses Darlehen die Wachstumsinitiativen des Unternehmens und die Marktanstrengungen unterstützen wird.
- Secured US$2.75 million in funding for strategic growth
- Established partnership with major pharmaceutical conglomerate Tasly
- Potential expansion in the global health product sector
- Short-term loan with one-year maturity
- Increased debt liability for the company
The
However, investors should note the short-term nature of the loan, maturing in just one year. This could potentially create refinancing pressure if the company doesn't generate sufficient cash flow to repay or secure new funding. The guarantee provided by Yoshitsu also adds a layer of financial risk to the parent company.
The strategic partnership with Tasly, a major Chinese pharmaceutical company, could open doors for product diversification and market expansion, particularly in the health products sector. This aligns well with global trends towards health and wellness, potentially boosting Yoshitsu's long-term growth trajectory.
Yoshitsu's move to secure funding for its Hong Kong subsidiary signals a strategic focus on the Asian market. Hong Kong serves as a important gateway for Japanese products entering mainland China, potentially allowing Yoshitsu to tap into the vast Chinese consumer base.
The partnership with Tasly is particularly intriguing. As a pharmaceutical conglomerate, Tasly brings valuable R&D capabilities to the table. This could enable Yoshitsu to develop innovative health products, differentiating itself in a crowded market. The global health products sector is projected to grow at a CAGR of
However, investors should monitor how effectively Yoshitsu leverages this partnership and funding to drive tangible growth, especially given the competitive landscape and evolving consumer preferences in the beauty and health sectors.
TOKYO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America, and the United Kingdom, today announced that its Hong Kong subsidiary, Tokyo Lifestyle Limited (“TLS”), entered into a US
Pursuant to the Agreement, TLS has secured US
Mr. Mei Kanayama, Principal Executive Officer of Yoshitsu, commented, “We are excited to secure this loan for our Hong Kong subsidiary. We believe that this loan not only highlights the confidence our investors have in our business model and growth potential, but also equips us with the necessary capital to advance our strategic initiatives. We are committed to utilizing these funds to enhance our operational capabilities and expand our market presence, ultimately delivering long-term value to our shareholders.”
About Yoshitsu Co., Ltd
Headquartered in Tokyo, Japan, Yoshitsu Co., Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, and other products in Hong Kong, Japan, North America, and the United Kingdom. The Company offers various beauty products (including cosmetics, skincare, fragrance, and body care products), health products (including over-the-counter drugs, nutritional supplements, and medical supplies and devices), sundry products (including home goods), and other products (including food and alcoholic beverages). The Company currently sells its products through directly-operated physical stores, through online stores, and to franchise stores and wholesale customers. For more information, please visit the Company's website at https://www.ystbek.co.jp/irlibrary/.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
Yoshitsu Co., Ltd
Investor Relations Department
Email: ir@ystbek.co.jp
Ascent Investor Relations LLC
Tina Xiao
President
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
FAQ
What is the amount and purpose of the strategic loan Yoshitsu (TKLF) secured?
When did Yoshitsu (TKLF) enter into the loan agreement and what is its duration?
Who provided the strategic loan to Yoshitsu's (TKLF) subsidiary?
What previous agreement did Yoshitsu (TKLF) have with Tasly?
